By Fineline Cube 
MicroPort Scientific Corp. (HKG: 0853) announced its 2025 full-year financial results, reporting a return to profitability with net profit of USD 38.427 million on group revenues of USD 1.105 billion, representing a 7.2% year-over-year increase.
Financial Highlights
| Item | Detail |
|---|---|
| Total Revenue | USD 1.105 billion (+7.2% YOY) |
| Net Profit | USD 38.427 million (return to profitability) |
| Global Access Platform Revenue | USD 163.9 million (+78.8% YOY) |
| Platform Status | Achieved breakeven during reporting period |
| Cardiovascular Intervention Margin | >20% adjusted net profit margin (2nd consecutive year) |
Business Segment Performance
- Surgical Robotics: Overseas sales grew 286.6% year-over-year
- Structural Heart Disease: Overseas sales increased 255.0% year-over-year
- Cardiovascular Intervention: Successfully navigated industry cycle through strategic transformation toward a “complete solution for coronary heart disease“
- Business Integration: Completed integration of structural heart disease and cardiac rhythm management businesses in 2025, optimizing operational efficiency
Strategic Platform – Global Access Commercialization
The company’s “Global Access” commercialization platform emerged as a key growth driver in 2025, enabling rapid international expansion of MicroPort’s innovative medical device portfolio. The platform’s success demonstrates the effectiveness of MicroPort’s strategy to diversify beyond domestic markets and capitalize on global demand for advanced cardiovascular solutions.
Key achievements:
- Generated USD 163.9 million in revenue (78.8% YOY growth)
- Achieved breakeven status during the reporting period
- Enabled triple-digit growth in overseas sales of core business segments
- Strengthened global distribution capabilities across key international markets
Market Impact & Outlook
- Global Medical Device Landscape: MicroPort’s return to profitability amid competitive pressures highlights successful execution of its international expansion strategy and operational optimization.
- Investment Case: With proven global commercialization capabilities and strong margins in core cardiovascular segments, MicroPort is well-positioned to continue its growth trajectory in 2026.
- Strategic Positioning: The integration of structural heart disease and cardiac rhythm management businesses creates synergies that enhance R&D efficiency and cross-selling opportunities.
- Growth Catalysts: Continued expansion of surgical robotics and structural heart disease solutions in international markets represents significant upside potential.
Forward‑Looking Statements
This brief contains forward-looking statements regarding financial performance, business strategy, and market outlook for MicroPort Scientific Corp. Actual results may differ due to risks including regulatory changes, competitive dynamics, and global economic conditions.-Fineline Info & Tech